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Chemotherapy-Induced Pulmonary Toxicity in Lung
Cancer Patients
Jay H. Ryu, MD
Many chemotherapy agents can induce pulmonary toxicity. Pneumotox.com is auseful internet site that provides a regularly updated list of drugs that have been
reported to cause pulmonary toxicity and the patterns of injury inflicted on the respiratory
system. These patterns of injury include not only parenchymal lung disease but also
pleural manifestations, airway diseases, pulmonary vascular abnormalities, mediastinal
changes, and neuromuscular effects.1–3 Pulmonary toxicity is uncommon with most
chemotherapy agents and typically consists of parenchymal lung injury (“pneumonitis” or
interstitial lung disease). This lung injury can be severe, sometimes resulting in progres-
sive respiratory failure and death, as illustrated by Yoh et al.4 in their study on
amrubicin-induced pulmonary toxicity published in this issue of the Journal of Thoracic
Oncology.4
As is true with most cases of drug-induced lung disease, the diagnosis of chemo-
therapy-induced lung disease can be difficult to confirm. The mode of onset (acute or
insidious) and timing of clinical manifestations associated with chemotherapy-induced
pulmonary toxicity is variable and may present during the initial cycle of treatment, after
subsequent cycles, or even years later as is the case with carmustine-associated pulmonary
fibrosis.1–3,5 On high-resolution computed tomography, ground-glass opacities, reticular
opacities, and/or consolidations are seen in a patchy distribution, usually bilateral. Lung
biopsy, whether bronchoscopic or surgical, generally does not yield findings specific for
chemotherapy-induced pulmonary toxicity. This is because the histopathologic features
seen in these cases are not unique to this form of lung injury and usually consist of various
interstitial patterns including nonspecific interstitial pneumonia, organizing pneumonia,
diffuse alveolar damage, eosinophilic pneumonia, granulomatous pneumonitis, and pul-
monary edema. These histopathologic patterns can be seen in a wide variety of clinical
contexts.6 A single chemotherapy agent can be associated with multiple injury pat-
terns.2,3,7,8 In most situations, the clinician relies on the temporal relationship between the
administration of chemotherapy and the onset of lung injury along with exclusion of other
potential causes, especially infections and metastatic disease, similar to the diagnostic
criteria used by Yoh et al.4
Several risk factors that predispose cancer patients to chemotherapy-induced pul-
monary toxicity have been described in the literature. These factors include patient’s age,
smoking history, cumulative dose of the administered drug, renal dysfunction, concomi-
tant chemotherapy or radiation therapy, and oxygen therapy.1,2,9 One particular risk factor
of interest in recent years is preexisting interstitial lung disease. In the study by Yoh et al.,4
the incidence of interstitial lung disease was 7% among 100 patients with small cell lung
cancer; three patients died of ambirubicin-induced pulmonary toxicity. Among 12 patients
with preexisting pulmonary fibrosis (defined by reticular or ground-glass opacities noted
on baseline chest radiograph or computed tomography scan), the incidence of ambirubi-
cin-induced pulmonary toxicity was 33%. On multivariate analysis, preexisting pulmo-
nary fibrosis was a significant independent risk factor for the development of ambirubicin-
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induced pulmonary toxicity. Preexisting interstitial lung
disease has also been described to be a risk factor for
pulmonary toxicity associated with other chemotherapy
agents including methotrexate, everolimus, temsirolimus, ox-
aliplatin, gefitinib, and erlotinib.2,10–15
Management of chemotherapy-induced pulmonary tox-
icity usually consists of discontinuing the offending drug and
administering corticosteroid therapy either orally or intrave-
nously, partly depending on the severity of pulmonary dis-
ease. Although the efficacy of corticosteroid therapy in this
clinical setting has not been rigorously tested, available literature
and anecdotal experience suggest that it is beneficial in amelio-
rating chemotherapy-induced pulmonary toxicity.1,2,9 Nonethe-
less, the beneficial response may be modest or transient and
sometimes even ineffective in preventing progressive respi-
ratory insufficiency and death.
Yoh et al.4 suggest avoiding the use of amrubicin in
patients with small cell lung cancer who have preexisting
pulmonary fibrosis because the risk of pulmonary toxicity is
substantial in this subset of patients. Based on their data, this
suggestion seems reasonable for the time being. However, it
raises questions regarding where the cutoff point should be in
diagnosing preexisting “pulmonary fibrosis” based on chest
imaging studies because computed tomography findings usu-
ally associated with interstitial lung disease can be encoun-
tered in asymptomatic individuals, especially the elderly.16
Additional studies in the future will hopefully clarify these
issues.
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